Cameron S Francis1, Sheila S Nazarian Mobin, Michael A Lypka, Elizabeth Rommer, Stephen Yen, Mark M Urata, Jeffrey A Hammoudeh. 1. Los Angeles, Calif.; and Houston, Texas From the Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles; Division of Plastic and Reconstructive Surgery, University of Southern California, Keck School of Medicine; Division of Plastic and Reconstructive Surgery, University of Texas Health Science Center; and Department of Oral and Maxillofacial Surgery, University of Southern California, School of Dentistry.
Abstract
BACKGROUND: Secondary alveolar cleft reconstruction using autologous iliac crest bone graft is currently the standard treatment for alveolar clefts. Although effective, harvesting autologous bone may result in considerable donor-site morbidity, most commonly pain and the potential for long-term sensory disturbances. In an effort to decrease patient morbidity, a novel technique using recombinant human bone morphogenetic protein (rhBMP)-2 encased in a demineralized bone matrix scaffold was developed as an alternative to autografting for secondary alveolar cleft reconstruction. METHODS: A chart review was conducted for the 55 patients who underwent secondary alveolar cleft reconstruction over a 2-year period with a mean follow-up of 21 months. Of these, 36 patients received rhBMP-2/demineralized bone matrix scaffold (including 10 patients with previously failed repairs using iliac crest bone grafting) and 19 patients underwent iliac crest bone grafting. Postoperatively, bone stock was evaluated using occlusal radiographs rated according to the Bergland and Chelsea scales. RESULTS: Alveolar clefts repaired using rhBMP-2/demineralized bone matrix scaffold were 97.2 percent successful compared with 84.2 percent with iliac crest bone grafting. Radiographically, initial repairs with rhBMP-2/demineralized bone matrix scaffold were superior to iliac crest bone grafting according to both Bergland and Chelsea scales, and significantly more patients in the rhBMP-2/demineralized bone matrix scaffold group had coronal bridging. The postoperative intraoral infection rate following iliac crest bone grafting was significantly greater than for rhBMP-2/demineralized bone matrix scaffold. The cost of rhBMP-2/demineralized bone matrix scaffold products was offset by cost savings associated with a reduction in operative time averaging 102 minutes. CONCLUSIONS: rhBMP-2 encased in a demineralized bone matrix scaffold appears to be a viable alternative for secondary alveolar cleft repair. Patients are spared donor-site morbidity and achieve excellent results, decreasing operative time, and increasing operating room use. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
BACKGROUND: Secondary alveolar cleft reconstruction using autologous iliac crest bone graft is currently the standard treatment for alveolar clefts. Although effective, harvesting autologous bone may result in considerable donor-site morbidity, most commonly pain and the potential for long-term sensory disturbances. In an effort to decrease patient morbidity, a novel technique using recombinant humanbone morphogenetic protein (rhBMP)-2 encased in a demineralized bone matrix scaffold was developed as an alternative to autografting for secondary alveolar cleft reconstruction. METHODS: A chart review was conducted for the 55 patients who underwent secondary alveolar cleft reconstruction over a 2-year period with a mean follow-up of 21 months. Of these, 36 patients received rhBMP-2/demineralized bone matrix scaffold (including 10 patients with previously failed repairs using iliac crest bone grafting) and 19 patients underwent iliac crest bone grafting. Postoperatively, bone stock was evaluated using occlusal radiographs rated according to the Bergland and Chelsea scales. RESULTS:Alveolar clefts repaired using rhBMP-2/demineralized bone matrix scaffold were 97.2 percent successful compared with 84.2 percent with iliac crest bone grafting. Radiographically, initial repairs with rhBMP-2/demineralized bone matrix scaffold were superior to iliac crest bone grafting according to both Bergland and Chelsea scales, and significantly more patients in the rhBMP-2/demineralized bone matrix scaffold group had coronal bridging. The postoperative intraoral infection rate following iliac crest bone grafting was significantly greater than for rhBMP-2/demineralized bone matrix scaffold. The cost of rhBMP-2/demineralized bone matrix scaffold products was offset by cost savings associated with a reduction in operative time averaging 102 minutes. CONCLUSIONS: rhBMP-2 encased in a demineralized bone matrix scaffold appears to be a viable alternative for secondary alveolar cleft repair. Patients are spared donor-site morbidity and achieve excellent results, decreasing operative time, and increasing operating room use. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
Authors: Christopher D Lopez; Paulo G Coelho; Lukasz Witek; Andrea Torroni; Michael I Greenberg; Dean L Cuadrado; Audrey M Guarino; Jonathan M Bekisz; Bruce N Cronstein; Roberto L Flores Journal: Plast Reconstr Surg Date: 2019-08 Impact factor: 4.730
Authors: Chen Shen; Lukasz Witek; Roberto L Flores; Nick Tovar; Andrea Torroni; Paulo G Coelho; F Kurtis Kasper; Mark Wong; Simon Young Journal: Tissue Eng Part A Date: 2020-10-01 Impact factor: 3.845
Authors: Chen Shen; Maxime M Wang; Lukasz Witek; Nick Tovar; Bruce N Cronstein; Andrea Torroni; Roberto L Flores; Paulo G Coelho Journal: Ann Plast Surg Date: 2021-12-01 Impact factor: 1.763
Authors: Cimara Fortes Ferreira; João Luiz Carlini; Ricardo de Souza Magini; José Nazareno Gil; André Luis Zétola Journal: Contemp Clin Dent Date: 2021-06-14
Authors: Jeremie D Oliver; Shihai Jia; Leslie R Halpern; Emily M Graham; Emma C Turner; John S Colombo; David W Grainger; Rena N D'Souza Journal: Tissue Eng Part B Rev Date: 2020-09-28 Impact factor: 7.376